INTRODUCTION
Coronary artery bypass grafting (CABG) surgery and percutaneous coronary intervention (PCI) are widely used revascularization strategies for coronary artery disease (CAD) which reduce mortality and improve quality of life1. Recent data suggested the superiority of CABG in preventing major cardiac events in patients with multivessel disease, particularly in patients with complex CAD and diabetes2.
The European System for Cardiac Operative Risk Evaluation (EuroSCORE) and the Society of Thoracic Surgeons (STS) 2008 Cardiac Surgery Risk Model are the most commonly used risk prediction models for cardiac surgery. These scoring systems are not only useful to assess the effect of specific clinical parameters on surgical outcomes, but also to aid in treatment selection, patient counseling, comparison of postoperative results, and quality improvement3. Besides, current mortality risk prediction models for CABG do not have a standardized approach in terms of both defining predictor variables and outcome. In addition, some problematic topics such as inadequate sample size, inappropriate handling of missing data, as well as suboptimal statistical techniques make these risk models debatable4. Need for calculator or computer make these models impractical for daily clinical use. Therefore, more practical risk modeling systems which predict morbidity and mortality are required.
CHADS2 and CHA2DS2-VASc scores are well-validated and proposed scoring systems to establish the risk of stroke in patients with non-valvular atrial fibrillation (AF). Additionally, CHA2DS2-VASc score components, such as age, hypertension, diabetes mellitus (DM), and prior cardiovascular event, are also traditional risk factors for CAD. Previous studies demonstrated the association between the CHA2DS2-VASc score and the severity of CAD5. Recent studies demonstrated the prognostic value of the CHA2DS2-VASc score in patients suffering from acute coronary syndrome (ACS)6.
Although CHA2DS2-VASc score is proposed as a predictor for immediate and late stroke after CABG, there is no data evaluating the prognostic value of CHA2DS2-VASc score in patients undergoing isolated CABG surgery7. When compared with the aforementioned risk models, the CHA2DS2-VASc score is a fast and simple method for risk evaluation that requires no calculator or computers. We sought for the prognostic value of CHA2DS2-VASc score in individuals undergoing isolated CABG surgery.
METHODS
Study Population
This study included patients who underwent isolated CABG at the Haseki Training and Research Hospital between January 2015 and August 2017. The study excluded patients with concomitant other surgeries such as valve repair or replacement. Patients with preoperative AF were also excluded. Emergent procedures were excluded since preoperative assessments, such as carotid ultrasound, were insufficient. Records of 555 patients were retrospectively reviewed. Of these, 22 (3.9%) patients had an insufficient record, 14 (2.5%) underwent off-pump surgery, and 23 (4.1%) underwent concomitant other cardiac surgery (valvular, ventricular aneurysms, acquired ventricular septal defect). Additional 32 (5.8%) patients who underwent emergent surgery were excluded from the study. All patients were operated by the same group of cardiovascular surgeons and anesthesiologists. Same techniques during CABG and myocardial protection were used.
The study population was retrospectively and consecutively analyzed by using our database, which was collected as a part of routine clinical practice. Data from each patient were obtained from a computerized system or a patient file. Demographic and laboratory variables including age, gender, body mass index (BMI), C-reactive protein, lipid panel, and clinical variables during hospitalization were recorded. Clinical variables included cardiopulmonary bypass (CPB) time, need for intra-aortic balloon (IAB), clamp time, total number of grafts, extubation time, bleeding revision, perioperative myocardial infarction (MI), sternal dehiscence, wound infection, cerebrovascular event (stroke or transient ischemic attack), mediastinitis, acute kidney injury, acute AF (lasting longer than one hour), intensive care unit (ICU) time, hospitalization time, and in-hospital mortality.
Risk Scores
SYNTAX I-II Score
The angiograms of the patients were evaluated by two experienced interventional cardiologists who were blind to the study. CAD was defined as a stenosis of more than 50% of the lumen diameter in any of the main coronary arteries. SYNTAX I-II scores were calculated by using the downloaded version (www.syntaxscore.com).
EuroSCORE I
Preoperative risk stratification was performed for all patients by using the downloaded version of the EuroSCORE system (euroscore.org).
CHA2DS2-VASc Score
CHA2DS2-VASc score was calculated for all patients by assigning one point for each of the following criteria: age 65-75 years, hypertension, DM, congestive heart failure or left ventricular ejection fraction (LVEF) < 40%, female sex, and vascular disease (defined as prior MI, complex aortic plaque, carotid disease, peripheral artery disease including intermittent claudication, and previous surgical or percutaneous intervention for abdominal aorta or vessels of upper or lower extremities). Two points were assigned for a history of stroke or transient ischemic attack or thromboembolism and age ≥ 75 years. Since all patients underwent coronary bypass surgery due to multiple CAD, CAD at index hospitalization was not taken into account. After the CHA2DS2-VASc score calculation, the study population was divided into two groups: low (L) (CHA2DS2-VASc <2 ) and high (H) (CHA2DS2-VASc ≥ 2) score groups.
Study Endpoints
A major adverse cardiac event (MACE) was the primary endpoint of this study. MACE was defined as a composite of in-hospital mortality, postoperative non-fatal MI, cardiac arrest requiring cardiopulmonary resuscitation, need for new mechanical circulatory support, and cerebrovascular event during intraoperative/postoperative hospitalization. In-hospital mortality was defined as death from all causes during intraoperative and postoperative hospitalization. The study was approved by the local ethics committee.
Statistical Analysis
Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS) software version 22.0 (IBM Corp. Armonk, New York, United States of America) and MedCalc bvba version 16 (Seoul, Korea). Normality of the data was analyzed with the Kolmogorov-Smirnov test. Continuous data were expressed as mean ± standard deviation (SD) and categorical data were expressed as percentages. Categorical variables between the groups were assessed with Chi-square test or Fisher’s exact test, whichever was suitable. Logistic regression analysis was used to identify the independent predictors of MACE. Differences between patient subgroups were tested using Mann-Whitney U test or Student's t-test, where appropriate. A P-value < 0.05 was considered statistically significant. Receiver-operating characteristic (ROC) curve graphics were used to determine the cut-off values of predictors for MACE.
RESULTS
Four hundred sixty-four patients who underwent elective isolated CABG surgery were included in the study. Patients were dichotomized depending on their CHA2DS2-VASc score. L and H score groups were compared as previously described. The L group included 238 patients (median age: 57 years interquartile range {IQR}: 52-63; 44 18.5% females) while the H group included 226 patients (median age: 64 years IQR: 55-67; 45 19.9% females). Hypertension, DM, and peripheral vascular disease (PVD) were more frequent in the H group (P<0.001, P<0.001, P=0.044, respectively) than in the L group. EuroSCORE I was similar in both groups (P=0.53). Anatomical based SYNTAX I score was similar in both groups, while clinical SYNTAX II-CABG score was significantly higher in the H group than in the L group (P=0.4, P=0.001, respectively). Postoperative MI was more frequent in the H group (P=0.006) than in the L group. Patients in the H group needed more İAB pump support (P=0.005) than those in the L group. Acute renal failure and mediastinitis in the postoperative period were more frequent in H group (P<0.001, P<0.001, respectively) than in the L group. Clinical, laboratory, and operative parameters were presented in Table 1 and Table 2. The H group had significantly higher in-hospital mortality and MACE rates than the L group (P<0.01).
[ Table Omitted - see PDF ]
DISCUSSION
We demonstrated, for the first time, that CHA2DS2-VASc score is an independent predictor for MACE in patients undergoing isolated CABG. Although CHA2DS2-VASc score includes only clinical parameters, it is as accurate as SYNTAX II-CABG, which includes a detailed angiographic evaluation.
CABG is a safe procedure with low rates of mortality and morbidity. However, the ability to accurately predict adverse outcomes and short- and long-term mortalities after CABG is an important issue that may allow planning preventive strategies and minimize complications8. EuroSCORE, STS risk calculator, and Parsonnet score are the most commonly used risk stratification models which include multiple variables, requiring online calculators for estimation of risk-related mortality and morbidity with CABG9. Nevertheless, these are complex and impractical tools to use at the bedside. Therefore, we still need models to quickly and easily predict risk at bedside, without the need for computational software. In practice, the bedside risk assessment not only provides the surgeon an objective, measurable risk profile to identify patients who require meticulous care, but it also provides the patients a more detailed knowledge of the risk related with the surgical procedure10.
CHA2DS2-VASc score is an easily applicable time-saving risk model which predicts the risk of thromboembolic events in patients with non-valvular AF in daily practice. CHA2DS2-VASc score components, such as older age, female gender, hypertension, DM, extracardiac arteriopathy, low LVEF, and preoperative stroke, and the presence of CAD were reported as predictors of early outcomes after CABG11.
The female sex has been reported as an independent predictor of short- and long-term mortalities and adverse events after CABG12. Although the female sex is included in both STS and EuroSCORE, evidence is controversial. Several studies concluded that the female sex is not a risk factor for post procedural mortality after CABG13. In our study, the female sex was not found to be associated with MACE, which is compatible with previous studies.
Increased age (> 60 years) has been reported as an independent predictor of mortality and adverse events after CABG14. In the EuroSCORE model, 60 years of age was accepted as a cut-off value, thus one point was assigned per each five years above 60 years. In the CHA2DS2-VASc score, one point was assigned for 65-75 of age years and two points were assigned for age ≥ 75 years. Compatible with previous studies, our study demonstrated an association between age and MACE14.
Heart transplantation (HT) and DM are not included in the EuroSCORE risk model. On the other hand, HT, DM, and age were the predominant variables causing high scores in our study. Age and HT were independent predictors for MACE in the present study. Although several studies revealed that patients with DM are at high risk for MACE and death after CABG, univariate analysis revealed that DM was not an independent predictor for MACE in the present study, like studies by Rajakaruna et al.15. These conflicting data may be related to defining the criteria of DM. DM was defined as the need for insulin or oral medication in the present study, while another study defined DM as the need for diet, oral medication, or insulin therapy16. Patients with insulin-dependent DM have a significantly higher rate of mortality and MACE than those with non-insulin-dependent DM17. We also did not classify DM as insulin-dependent or non-dependent. These might explain the different outcome associated with diabetes on early mortality in the present study.
Although there is conflicting data in the literature, we showed that preexisting HT is a poor predictor for patients undergoing isolated CABG18. CABG has been shown to be superior to medical therapy alone in patients with preoperative low LVEF19. Besides, Dalen et al. showed that the reduced ejection fraction doubled the risk of early postoperative death20. Compatible with the previous studies, patients with left ventricular systolic dysfunction and symptoms of heart failure had significantly high in-hospital mortality and morbidity in our study9.
Similar to our study, numerous studies have demonstrated that the PVD was an independent predictor of early mortality and poor short-term outcome after CABG21. On the other hand, the association between PVD and early mortality was not confirmed in some studies22.
History of stroke has been found to be associated with mortality and increased early and late postoperative stroke23. In line with the literature, the present study demonstrated that a history of preoperative stroke was associated with poor outcome.
Consequently, when we performed univariate analysis of each CHA2DS2-VASc score component, congestive heart failure or ejection fraction < 40%, age, hypertension, cerebrovascular accident, and PVD were significantly associated with MACE in patients undergoing after isolated CABG, whereas DM and sex were not.
Several studies have demonstrated an association between the CHA2DS2-VASc score and increased mortality and non-fatal adverse cardiovascular outcomes in different clinical conditions, regardless of the presence of AF24. Recently, Hamid et al. observed high mortality in the patients undergoing transcatheter aortic valve replacement who had CHA2DS2-VASc score > 6. Therefore CHA2DS2-VASc score was proposed as a simple tool for the identification of high-risk patients for short-term and mid-term mortalities in patients undergoing transcatheter aortic valve replacement (TAVR)25.
This the first study which aimed to investigate the value of CHA2DS2-VASc score to estimate MACE in patients undergoing isolated CABG surgery. Biancari et al. demonstrated predictive accuracy of CHA2DS2-VASc score for immediate and late stroke in patients after CABG without pre- and postoperative AF. They also demonstrated that CHA2DS2-VASc score is a predictor for late all-cause mortality and cardiovascular mortality8. But there is no data specifically evaluating the value of CHA2DS2-VASc score for prediction of in-hospital mortality and MACE in patients undergoing isolated CABG.
Limitation
The major limitation of our study is that we focused on the CHA2DS2-VASc score, which only includes the preoperative variables, and we did not take operative and postoperative variables into account. In the recent years, more complex preoperative patient profile was being referred for CABG due to improved medical treatment options and achievements of interventional cardiology. As preoperative variables may have limited predictor role without combination with operative and postoperative variables, larger studies including preoperative, operative, and postoperative variables are required. The second limitation was that the surgery was performed by a particular surgeon group. And another limitation is the retrospective nature of the study. So this study is single-centered and may not be generalized to all patient groups.
CONCLUSION
We showed that CHA2DS2-VASc score may predict in-hospital mortality and MACE in patients undergoing isolated CABG in our study population. CHA2DS2-VASc score is a handy risk stratification score and easily appliable at bedside without any computational software. Further studies are required to assess the validity of our findings in larger populations.
Authors’ roles & responsibilities | |
---|---|
MK | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published. |
SO | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published. |
MZ | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published. |
No financial support.
1 Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-15. doi:10.1056/NEJMoa0805796.
2 Mohr FW, Morice MC, Kappetein, Feldman TE, Ståhle E, Colombo A, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629-38. doi:10.1016/S0140-6736(13)60141-5.
3 Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al; Society of Thoracic Surgeons Quality Measurement Task Force. The society of thoracic surgeons 2008 cardiac surgery risk models: part 1 - coronary artery bypass grafting surgery. Ann Thorac Surg. 2009;88 (1 Suppl):S2-22. doi:10.1016/j.athoracsur.2009.05.053.
4 Karim MN, Reid CM, Cochrane A, Tran L, Alramadan M, Hossain MN, et al. Mortality risk prediction models for coronary artery bypass graft surgery: current scenario and future direction. J Cardiovasc Surg. 2017;58(6):931-42. doi:10.23736/S0021-9509.17.09965-7.
5 Cetin M, Cakici M, Zencir C, Tasolar H, Baysal E, Balli M, et al. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol. 2014;113(6):950-6. doi:10.1016/j.amjcard.2013.11.056.
6 Chua SK, Lo HM, Chiu CZ, Shyu KG. CHA2DS2-VASc score predicts intracoronary thrombus burden in patients with ST-elevation myocardial infarction. Biomed Res. 2017;28(18):8050-4.
7 Biancari F, Asim Mahar MA, Kangasniemi OP. CHADS2 and CHA2DS2-VASc scores for prediction of immediate and late stroke after coronary artery bypass graft surgery. J Stroke Cerebrovasc Dis. 2013;22(8):1304-11. doi:10.1016/j.jstrokecerebrovasdis.2012.11.004.
8 Antunes PE, de Oliveira JF, Antunes MJ. Risk-prediction for postoperative major morbidity in coronary surgery. Eur J Cardiothorac Surg. 2009;35(5):760-6; discussion 766-7. doi:10.1016/j.ejcts.2008.10.046.
9 Kamal YA, Al-Elwany S, Ghoneim A, El-Minshawy A. Traditional predictors of in-hospital mortality after coronary artery bypass grafting: Current status. Cardiothorac Vasc Sci. 2017;1(2):1-5. doi:10.15761/CVS.1000107.
10 Ad N, Barnett SD, Speir AM. The performance of the EuroSCORE and the society of thoracic surgeons mortality risk score: the gender factor. Interact Cardiovasc Thorac Surg. 2007;6(2):192-5. doi:10.1510/icvts.2006.138313.
11 Kamal YA, Al-Elwany SE, Ghoneim A, El-Minshawy AK. Predictors of early adverse events after isolated coronary artery bypass grafting: Current status. Austin J Clin Cardiolog [Internet]. 2017 [cited 2019 Apr 27];4(2):1059. Available from: http://austinpublishinggroup.com/clinical-cardiology/fulltext/ajcc-v4-id1059.pdf.
12 Alam M, Bandeali SJ, Kayani WT, Ahmad W, Shahzad SA, Jneid H, et al. Comparison by meta-analysis of mortality after isolated coronary artery bypass grafting in women versus men. Am J Cardiol. 2013;112(3):309-17. doi:10.1016/j.amjcard.2013.03.034.
13 Faerber G, Zacher M, Reents W, Boergermann J, Kappert U, Boening A, et al. Female sex is not a risk factor for post procedural mortality in coronary bypass surgery in the elderly: A secondary analysis of the GOPCABE trial. PLoS One. 2017;12(8):e0184038. doi:10.1371/journal.pone.0184038.
14 Safaie N, Montazerghaem H, Jodati A, Maghamipour N. In-hospital complications of coronary artery bypass graft surgery in patients older than 70 years. J Cardiovasc Thorac Res. 2015;7(2):60-2. doi:10.15171/jcvtr.2015.13.
15 Rajakaruna C, Rogers CA, Suranimala C, Angelini GD, Ascione R. The effect of diabetes mellitus on patients undergoing coronary surgery: a risk-adjusted analysis. J Thorac Cardiovasc Surg. 2006;132(4):802-10. doi:10.1016/j.jtcvs.2006.05.056.
16 Szabó Z, Håkanson E, Svedjeholm R. Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 2002;74(3):712-9. doi:10.1016/S0003-4975(02)03778-5.
17 Raza S, Sabik JF, Ainkaran P, Blackstone EH. Coronary artery bypass grafting in diabetics: a growing health care cost crisis. J Thorac Cardiovasc Surg. 2015;150(2):304-12.e2. doi:10.1016/j.jtcvs.2015.03.041.
18 Vavlukis M, Borozanov V, Georgievska-Ismail LJ, Bosevski M, Taneva B, Kostova N, et al. Arterial hypertension in patients with coronary artery disease treated with surgical myocardial revascularization. Bratisl Lek Listy [Internet]. 2007 [cited 2019 Apr 27];108(7):301-6. Available from: https://core.ac.uk/download/pdf/35341402.pdf.
19 Wrobel K, Stevens SR, Jones RH, Selzman CH, Lamy A, et al. Influence of baseline characteristics, operative conduct and postoperative course on 30-day outcomes of coronary artery bypass grafting among patients with left ventricular dysfunction: results from the surgical treatment for ischemic heart failure (STICH) trial. Circulation 2015;25;132(8):720-30. doi:10.1161/CIRCULATIONAHA.114.014932.
20 Dalen M, Lund LH, Ivert T, Holzmann MJ, Sartipy U. Survival after coronary artery bypass grafting in patients with preoperative heart failure and preserved vs reduced ejection fraction. JAMA Cardiol. 2016;1(5):530-8. doi:10.1001/jamacardio.2016.1465.
21 Birkmeyer JD, O'Connor GT, Quinton HB, Ricci MA, Morton JR, Leavitt BJ, et al. The effect of peripheral vascular disease on in-hospital mortality rates with coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. J Vasc Surg [Internet]. 1995 [cited 2019 Apr 27];21(3):445-52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7877226.
22 van Straten AH, Firanescu C, Soliman Hamad MA, Tan ME, Woorst JF, Martens EJ, et al. Peripheral vascular disease as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population. Ann Thorac Surg. 2010;89(2):414-20. doi:10.1016/j.athoracsur.2009.11.036.
23 Anyanwu AC, Filsoufi F, Salzberg SP, Bronster DJ, Adams DH. Epidemiology of stroke after cardiac surgery in the current era. J Thorac Cardiovasc Surg. 2007;134(5):1121-7. doi:10.1016/j.jtcvs.2007.06.031
24 Puurunen MK, Kiviniemi T, Schlitt A, Rubboli A, Dietrich B, Karjalainen P, et al. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Thromb Res. 2014;133(4):560-6. doi:10.1016/j.thromres.2014.01.007.
25 Hamid T, Choudhury TR, Anderson SG, et al. Does the CHA2DS2-VASc score predict procedural and short-term outcomes in patients undergoing transcatheter aortic valve implantation? Openheart. 2015;2(1):e000170. doi:10.1136/openhrt-2014-000170.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2019. This work is published under https://creativecommons.org/licenses/by/4.0/deed.en (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Need for calculator or computer make these models impractical for daily clinical use. [...]more practical risk modeling systems which predict morbidity and mortality are required. Clinical variables included cardiopulmonary bypass (CPB) time, need for intra-aortic balloon (IAB), clamp time, total number of grafts, extubation time, bleeding revision, perioperative myocardial infarction (MI), sternal dehiscence, wound infection, cerebrovascular event (stroke or transient ischemic attack), mediastinitis, acute kidney injury, acute AF (lasting longer than one hour), intensive care unit (ICU) time, hospitalization time, and in-hospital mortality. Two points were assigned for a history of stroke or transient ischemic attack or thromboembolism and age ≥ 75 years. Since all patients underwent coronary bypass surgery due to multiple CAD, CAD at index hospitalization was not taken into account. [...]these are complex and impractical tools to use at the bedside. [...]we still need models to quickly and easily predict risk at bedside, without the need for computational software.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer